G1 Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GTHX research report →
About the company
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens.
- CEO
- John E. Bailey Jr.
- IPO
- 2017
- Employees
- 100
- HQ
- Research Triangle Park, NC, US
Price Chart
- Market Cap
- $377.75M
- P/E
- -7.70
- P/S
- 4.58
- P/B
- 10.47
- EV/EBITDA
- -11.74
- Div Yield
- 0.00%
- Gross Margin
- 91.28%
- Op Margin
- -47.91%
- Net Margin
- -58.13%
- ROE
- -92.13%
- ROIC
- -43.05%
- Revenue
- $82.51M · 60.84%
- Net Income
- $-47,967,000 · 67.49%
- EPS
- $-0.93 · 72.49%
- Op Income
- $-39,527,000
- FCF YoY
- 70.31%
- 52W High
- $7.19
- 52W Low
- $1.08
- 50D MA
- $5.57
- 200D MA
- $4.01
- Beta
- 1.68
- Avg Volume
- 2.23M
Get TickerSpark's AI analysis on GTHX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 24 | Secor Alicia | sell | 20,000 |
| Sep 18, 24 | Secor Alicia | sell | 30,000 |
| Sep 18, 24 | Secor Alicia | other | 10,000 |
| Sep 18, 24 | Secor Alicia | sell | 30,000 |
| Sep 18, 24 | Secor Alicia | sell | 30,000 |
| Sep 18, 24 | Thomas Monica R. | sell | 138,151 |
| Sep 18, 24 | Thomas Monica R. | other | 6,674 |
| Sep 18, 24 | Thomas Monica R. | sell | 55,875 |
| Sep 18, 24 | Thomas Monica R. | sell | 150,000 |
| Sep 18, 24 | Flowers Cynthia Louise | sell | 20,000 |
Our GTHX coverage
Recent articles, reports, and earnings notes.
No research on GTHX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GTHX report →Similar companies
Peers in the same neighborhood.